Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M.

World Psychiatry. 2016 Oct;15(3):195-204. doi: 10.1002/wps.20341.

2.

Acute effects of cannabis on breath-holding duration.

Farris SG, Metrik J.

Exp Clin Psychopharmacol. 2016 Aug;24(4):305-12. doi: 10.1037/pha0000075.

PMID:
27454678
3.

The Role of the Endocannabinoid System in the Brain-Gut Axis.

Sharkey KA, Wiley JW.

Gastroenterology. 2016 Aug;151(2):252-66. doi: 10.1053/j.gastro.2016.04.015. Review.

PMID:
27133395
4.

Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, Barnes AJ, Huestis MA, Le Foll B.

Drug Alcohol Depend. 2016 Apr 1;161:298-306. doi: 10.1016/j.drugalcdep.2016.02.020.

PMID:
26925704
5.

Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis.

D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan 1;1(1):60-67.

6.

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL.

Neuropsychopharmacology. 2016 Jul;41(8):1974-82. doi: 10.1038/npp.2015.367.

PMID:
26708108
7.

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC.

Biol Psychiatry. 2016 Jun 15;79(12):997-1005. doi: 10.1016/j.biopsych.2015.08.021.

PMID:
26432420
8.

Marijuana's acute effects on cognitive bias for affective and marijuana cues.

Metrik J, Aston ER, Kahler CW, Rohsenow DJ, McGeary JE, Knopik VS.

Exp Clin Psychopharmacol. 2015 Oct;23(5):339-50. doi: 10.1037/pha0000030.

9.

Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence.

Prud'homme M, Cata R, Jutras-Aswad D.

Subst Abuse. 2015 May 21;9:33-8. doi: 10.4137/SART.S25081. Review.

10.

An animal model of female adolescent cannabinoid exposure elicits a long-lasting deficit in presynaptic long-term plasticity.

Lovelace JW, Corches A, Vieira PA, Hiroto AS, Mackie K, Korzus E.

Neuropharmacology. 2015 Dec;99:242-55. doi: 10.1016/j.neuropharm.2015.04.034.

11.

Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.

Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC.

Neuropsychopharmacology. 2015 Aug;40(9):2124-34. doi: 10.1038/npp.2015.53.

12.

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV.

Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014.

13.

Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users.

Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, van der Wee NJ, Durieux J, Manai M, Hommel B.

Psychopharmacology (Berl). 2015 Mar;232(6):1123-34. doi: 10.1007/s00213-014-3749-1.

14.

Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

Lee D, Vandrey R, Mendu DR, Murray JA, Barnes AJ, Huestis MA.

Drug Test Anal. 2015 Jun;7(6):494-501. doi: 10.1002/dta.1718.

15.

Momentary positive and negative affect preceding marijuana use events in youth.

Shrier LA, Ross CS, Blood EA.

J Stud Alcohol Drugs. 2014 Sep;75(5):781-9.

16.

Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex.

Cathel AM, Reyes BA, Wang Q, Palma J, Mackie K, Van Bockstaele EJ, Kirby LG.

Eur J Neurosci. 2014 Oct;40(8):3202-14. doi: 10.1111/ejn.12690.

17.

Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Lazenka MF, David BG, Lichtman AH, Nestler EJ, Selley DE, Sim-Selley LJ.

Biochem Pharmacol. 2014 Oct 1;91(3):380-9. doi: 10.1016/j.bcp.2014.07.024.

18.

Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users.

Skosnik PD, Krishnan GP, D'Souza DC, Hetrick WP, O'Donnell BF.

Neuropsychopharmacology. 2014 Dec;39(13):3087-99. doi: 10.1038/npp.2014.166.

19.

Gone to Pot - A Review of the Association between Cannabis and Psychosis.

Radhakrishnan R, Wilkinson ST, D'Souza DC.

Front Psychiatry. 2014 May 22;5:54. doi: 10.3389/fpsyt.2014.00054. Review.

20.

Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice.

Morgan DJ, Davis BJ, Kearn CS, Marcus D, Cook AJ, Wager-Miller J, Straiker A, Myoga MH, Karduck J, Leishman E, Sim-Selley LJ, Czyzyk TA, Bradshaw HB, Selley DE, Mackie K.

J Neurosci. 2014 Apr 9;34(15):5152-63. doi: 10.1523/JNEUROSCI.3445-12.2014.

Items per page

Supplemental Content

Support Center